Abstract

The current program relies heavily on the ability to produce recombinant monoclonal anfibodies by transient transfection. Drs. Steinman and Ravetch will make use of such reagents in targeting DC subsets in vivo and in producing modified anfibodies that are capable of DC targefing and acfivafion. Because they will be used in vivo and in tissue culture experiments uniform quality control for these reagents including LPS tesfing will be crifical. Dr. Nussenzweig will produce hundreds of different human monoclonal anfibodies by the same transfecfion method in his part ofthe program for tesfing in HIV binding and neutralizafion assays. These assays will require hundreds of micrograms of the anfibody reagents. The proposed core will produce recombinant anfibodies for all ofthe participants in the program and in addifion store and distribute the reagents to collaborators and to the scientific community.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
1P01AI081677-01A1
Application #
7774824
Study Section
Special Emphasis Panel (ZAI1-KS-I (S3))
Project Start
2009-09-25
Project End
2014-08-31
Budget Start
2009-09-25
Budget End
2010-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$246,571
Indirect Cost

  Institution

Name
Rockefeller University
Department
Type
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065

  Publications

Bournazos, Stylianos; Gazumyan, Anna; Seaman, Michael S et al. (2016) Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency. Cell 165:1609-1620
Lu, Ching-Lan; Murakowski, Dariusz K; Bournazos, Stylianos et al. (2016) Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352:1001-4
Pantel, Austin; Teixeira, Angela; Haddad, Elias et al. (2014) Direct type I IFN but not MDA5/TLR3 activation of dendritic cells is required for maturation and metabolic shift to glycolysis after poly IC stimulation. PLoS Biol 12:e1001759
Halper-Stromberg, Ariel; Lu, Ching-Lan; Klein, Florian et al. (2014) Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158:989-999
Bournazos, Stylianos; Klein, Florian; Pietzsch, John et al. (2014) Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158:1243-1253
DiLillo, David J; Tan, Gene S; Palese, Peter et al. (2014) Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc?R interactions for protection against influenza virus in vivo. Nat Med 20:143-51
Mollah, Shamim A; Dobrin, Joseph S; Feder, Rachel E et al. (2014) Flt3L dependence helps define an uncharacterized subset of murine cutaneous dendritic cells. J Invest Dermatol 134:1265-1275
Anandasabapathy, Niroshana; Feder, Rachel; Mollah, Shamim et al. (2014) Classical Flt3L-dependent dendritic cells control immunity to protein vaccine. J Exp Med 211:1875-91
Gruell, Henning; Bournazos, Stylianos; Ravetch, Jeffrey V et al. (2013) Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. J Virol 87:8535-44
Klein, Florian; Mouquet, Hugo; Dosenovic, Pia et al. (2013) Antibodies in HIV-1 vaccine development and therapy. Science 341:1199-204

Showing the most recent 10 out of 24 publications